Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

被引：0
|
作者：
Loupakis, F. [1 ,2 ,3 ,4 ,5 ]
Cremolini, C. [1 ,2 ,3 ,4 ,5 ]
Perrone, G. [1 ,2 ,3 ,4 ,5 ]
Stasi, I. [1 ,2 ,3 ,4 ,5 ]
Salvatore, L. [1 ,2 ,3 ,4 ,5 ]
Vincenzi, B. [1 ,2 ,3 ,4 ,5 ]
Ruzzo, A. [1 ,2 ,3 ,4 ,5 ]
Ronzoni, M. [1 ,2 ,3 ,4 ,5 ]
Bencardino, K. [1 ,2 ,3 ,4 ,5 ]
Falcone, A. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Azienda USL 6, Dept Oncol, Livorno, Italy
[2] Campus Biomed Univ, Rome, Italy
[3] Univ Urbino, Dept Biomol Sci, I-61029 Urbino, Italy
[4] Ist Sci San Raffaele, I-20132 Milan, Italy
[5] Univ Pisa, Dept Oncol, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4021
引用
收藏
页数：2
相关论文
共 50 条
  • [31] KRAS wild-type status predicts response to cetuximab in metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (7): : 365 - 365
  • [32] Rechallenge with cetuximab 1 irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with
    Daniele, Rossini
    Daniele, Santini
    Chiara, Cremolini
    Lisa, Salvatore
    Sara, Lonardi
    Emanuela, Dell' Aquila
    Giuseppe, Aprile
    Fotios, Loupakis
    Bruno, Vincenzi
    Francesca, Battaglin
    Vanessa, Buoro
    Emiliano, Tamburini
    Deborah, Basile
    Domenico, Corsi
    Iacopo, Fioroni
    Gianluca, Masi
    Carlotta, Antoniotti
    Beatrice, Borelli
    Marzia, Del Re
    Giuseppe, Tonini
    Alfredo, Falcone
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
    F Loupakis
    A Ruzzo
    C Cremolini
    B Vincenzi
    L Salvatore
    D Santini
    G Masi
    I Stasi
    E Canestrari
    E Rulli
    I Floriani
    K Bencardino
    N Galluccio
    V Catalano
    G Tonini
    M Magnani
    G Fontanini
    F Basolo
    A Falcone
    F Graziano
    British Journal of Cancer, 2009, 101 : 715 - 721
  • [34] KRAS wild-type tumors benefit from cetuximab
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2009, 6 (7) : 374 - 374
  • [35] KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
    Loupakis, F.
    Ruzzo, A.
    Cremolini, C.
    Vincenzi, B.
    Salvatore, L.
    Santini, D.
    Masi, G.
    Stasi, I.
    Canestrari, E.
    Rulli, E.
    Floriani, I.
    Bencardino, K.
    Galluccio, N.
    Catalano, V.
    Tonini, G.
    Magnani, M.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    Graziano, F.
    BRITISH JOURNAL OF CANCER, 2009, 101 (04) : 715 - 721
  • [36] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope Elizabeth
    Morse, Michael
    Blobe, Gerard C.
    Zafar, Yousuf
    Hsu, Shiaowen David
    Arrowood, Christy
    Ley, Sherri Ha
    Dropkin, Evan
    Niedzwiecki, Donna
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?
    Watanabe, Toshiyasu
    Shinozaki, Eiji
    Kijima, Sho
    Ohhara, Yoshihito
    Kuboki, Yasutoshi
    Takagi, Koichi
    Ozaka, Masato
    Ogura, Mariko
    Kikuchi, Yoshinori
    Suenaga, Mitsukuni
    Chin, Keisho
    Matsusaka, Satoshi
    Koike, Junichi
    Funahashi, Kimihiko
    Urita, Yoshihisa
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    Kaneko, Hironori
    Sugimoto, Motonobu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [38] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G)
    Sakai, Daisuke
    Taniguchi, Hiroya
    Sugimoto, Naotoshi
    Tamura, Takao
    Nishina, Tomohiro
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Sakamoto, Takeshi
    Okuda, Hiroyuki
    Satoh, Taroh
    Tsushima, Takahiro
    Makiyama, Akitaka
    Tsuda, Takashi
    Hosokawa, Ayumu
    Kuramochi, Hidekazu
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Yasui, Hisateru
    Ishida, Hiroyasu
    Tsuji, Akihito
    Otsu, Satoshi
    Shimokawa, Hozumi
    Baba, Eishi
    Sato, Mikio
    Matsumoto, Shigemi
    Ozaki, Yukinori
    Shinozaki, Katsunori
    Tamagawa, Hiroshi
    Goto, Masahiro
    Kadowaki, Shigenori
    Fujii, Hirofumi
    Koh, Yasuhiro
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Kishimoto, Junji
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 11 - 21
  • [39] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Utsunomiya, Setsuo
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 688 - 693
  • [40] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Tomoya Yokota
    Daisuke Takahari
    Takashi Shibata
    Takashi Ura
    Setsuo Utsunomiya
    Yoshitaka Inaba
    Hidekazu Yamaura
    Yozo Sato
    Mina Najima
    Hiroki Kawai
    Masahiro Tajika
    Akira Sawaki
    Yasushi Yatabe
    Kei Muro
    Investigational New Drugs, 2011, 29 : 688 - 693
12345